Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas.

Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A.

Nat Commun. 2013;4:1701. doi: 10.1038/ncomms2660.

2.

Relation between smoking history and gene expression profiles in lung adenocarcinomas.

Staaf J, Jönsson G, Jönsson M, Karlsson A, Isaksson S, Salomonsson A, Pettersson HM, Soller M, Ewers SB, Johansson L, Jönsson P, Planck M.

BMC Med Genomics. 2012 Jun 7;5:22.

3.

Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers.

Woenckhaus M, Klein-Hitpass L, Grepmeier U, Merk J, Pfeifer M, Wild P, Bettstetter M, Wuensch P, Blaszyk H, Hartmann A, Hofstaedter F, Dietmaier W.

J Pathol. 2006 Oct;210(2):192-204.

PMID:
16915569
4.

Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.

Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, Campbell J, Williams AC, Hwang D, Zhu CQ, Buys TP, Yee J, English JC, Macaulay C, Tsao MS, Gazdar AF, Minna JD, Lam S, Lam WL.

PLoS Med. 2010 Jul 27;7(7):e1000315. doi: 10.1371/journal.pmed.1000315.

5.

Progressive lung cancer determined by expression profiling and transcriptional regulation.

Han N, Dol Z, Vasieva O, Hyde R, Liloglou T, Raji O, Brambilla E, Brambilla C, Martinet Y, Sozzi G, Risch A, Montuenga LM; EUELC Consortium., Brass A, Field JK.

Int J Oncol. 2012 Jul;41(1):242-52. doi: 10.3892/ijo.2012.1421. Epub 2012 Mar 28.

PMID:
22469662
6.

Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas.

McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M.

Clin Cancer Res. 2002 Apr;8(4):1127-38.

8.

ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis.

Fujiwara T, Hiramatsu M, Isagawa T, Ninomiya H, Inamura K, Ishikawa S, Ushijima M, Matsuura M, Jones MH, Shimane M, Nomura H, Ishikawa Y, Aburatani H.

Lung Cancer. 2012 Jan;75(1):119-25. doi: 10.1016/j.lungcan.2011.05.028. Epub 2011 Jul 6.

PMID:
21737174
9.

Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas.

Valbuena A, Suárez-Gauthier A, López-Rios F, López-Encuentra A, Blanco S, Fernández PL, Sánchez-Céspedes M, Lazo PA.

Lung Cancer. 2007 Dec;58(3):303-9. Epub 2007 Aug 8.

PMID:
17689819
10.

Topographic analysis of K- ras mutations in histologically normal lung tissues and tumours of lung cancer patients.

Keohavong P, Mady HH, Gao WM, Siegfried JM, Luketich JD, Melhem MF.

Br J Cancer. 2001 Jul 20;85(2):235-41.

11.

Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.

Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA.

Am J Respir Crit Care Med. 2005 Sep 15;172(6):729-37. Epub 2005 Jun 23.

12.
13.

Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach.

Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL, Stass SA, Jiang F.

Oncogene. 2006 Apr 27;25(18):2628-35.

PMID:
16369491
14.

Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions.

Davidson B, Stavnes HT, Risberg B, Nesland JM, Wohlschlaeger J, Yang Y, Shih IeM, Wang TL.

Hum Pathol. 2012 May;43(5):684-94. doi: 10.1016/j.humpath.2011.06.015. Epub 2011 Sep 19.

PMID:
21937081
15.

Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas.

Gharib TG, Chen G, Huang CC, Misek DE, Iannettoni MD, Hanash SM, Orringer MB, Beer DG.

Clin Lung Cancer. 2004 Mar;5(5):307-12.

PMID:
15086970
16.
17.

Secreted phosphoprotein 1 upstream invasive network construction and analysis of lung adenocarcinoma compared with human normal adjacent tissues by integrative biocomputation.

Sun Y, Wang L, Jiang M, Huang J, Liu Z, Wolfl S.

Cell Biochem Biophys. 2010 Apr;56(2-3):59-71. doi: 10.1007/s12013-009-9071-6.

PMID:
19949890
18.

NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation.

Chen PM, Wu TC, Cheng YW, Chen CY, Lee H.

Oncotarget. 2015 Jun 10;6(16):14274-89.

19.

NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression.

Yamaguchi T, Hosono Y, Yanagisawa K, Takahashi T.

Cancer Cell. 2013 Jun 10;23(6):718-23. doi: 10.1016/j.ccr.2013.04.002. Review.

20.

Establishment and expression profiling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers.

Lam DC, Girard L, Suen WS, Chung LP, Tin VP, Lam WK, Minna JD, Wong MP.

J Thorac Oncol. 2006 Nov;1(9):932-42.

Supplemental Content

Support Center